Abstract A85: Preclinical evaluation of the radiolabeled bispecific T-cell engager 89Zr-AMG 211 targeting CEA-positive tumors by Waaijer, S.J.H., Warnders, F.J., Lub-de Hooge, M.N., Stienen, S., Friedrich, M., Sternjak, A., Pieslor, P.C., Cheung, K., Terwisscha van Scheltinga, A.G.T., Schröder, C.P., de Vries, E.G.E.

Get full text

535 Tumor targeting and tissue distribution of solitomab (AMG 110; anti-EpCAM BiTE®) in human EpCAM-positive tumor bearing mice by Warnders, F.J, Waaijer, S, Lub-de Hooge, M.N, Friedrich, M, van Scheltinga, A.G.T. Terwisscha, Deegen, P, Stienen, S.K, Pieslor, P.C, Cheung, H.K, Kosterink, J.G.W, de Vries, E.G.E

Get full text

19 Targeting Cellular Resistance Against Cisplatin-Induced Apoptosis by Meijer, A, Kruyt, F.A.E, Meersma, G.J, Quax, W.J, Van der Zee, A.G.J, van Scheltinga, A.G.T. Terwisscha, De Vries, E.G.E, De Jong, S

Get full text

315 ImmunoPET and Biodistribution with Human Epidermal Growth Factor Receptor 3 Targeting Radiolabeled Antibody 89Zr-GE-huMAb-HER3 by van Scheltinga, A.G.T. Terwisscha, Lub-de Hooge, M.N, Abiraj, K, Schröder, C.P, Pot, L, Bossenmaier, B, Pickl, M, Friess, T, Kosterink, J.G.W, de Vries, E.G.E

Get full text